Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

الاستراتيجية الوطنية للتحصين للأعوام ٢٠١٧-٢٠٢٢


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    161
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EX03 VOTRIENT B Pazopanib HCl - 400mg 400mg Tablet, film coated 66,323,011 L.L
N02AJ14 LENIZAK B Tramadol HCl - 75mg, Dexketoprofen - 25mg Tablet, film coated 494,534 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
A02BC06 DEXILANT B Dexlansoprazole - 30mg 30mg Capsule, delayed release 1,595,141 L.L
C07AB07 CONCOR B Bisoprolol fumarate - 5mg 5mg Tablet, film coated 870,164 L.L
C10BA03 PRAVAFEN B Pravastatin sodium - 40mg, Fenofibrate - 160mg Capsule, hard 1,264,556 L.L
L01EX03 VOTRIENT B Pazopanib HCl - 400mg 400mg Tablet, film coated 72,470,021 L.L
M01AE11 SURGAM B Tiaprofenic acid - 300mg 300mg Tablet 849,308 L.L
N02AX02 TRAMAL B Tramadol HCl - 50mg 50mg Capsule 349,399 L.L
A02BC06 DEXILANT B Dexlansoprazole - 60mg 60mg Capsule, delayed release 2,375,914 L.L
C09DA03 CO-DIOVAN B Valsartan - 160mg, Hydrochlorothiazide - 25mg Tablet, film coated 901,718 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 20mg Tablet, film coated 1,251,117 L.L
L01EX03 VOTRIENT B Pazopanib HCl - 200mg 200mg Tablet, film coated 31,567,504 L.L
M01AE17 KETESSE B Dexketoprofen (trometamol) - 25mg 25mg Tablet, film coated 399,121 L.L
N02AX02 TRAMAL 100MG B Tramadol HCl - 100mg/2ml 100mg/2ml Injectable solution 243,235 L.L
N03AX18 VIMPAT B Lacosamide - 150mg 150mg Tablet, film coated 11,754,896 L.L
A02BC07 DEXPURE B Dexrabeprazole sodium - 10mg 10mg Tablet, enteric coated 517,379 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 40mg Tablet, film coated 1,358,625 L.L
J01DD04 ROCEPHIN IV B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 757,927 L.L
L01EX03 VOTRIENT B Pazopanib HCl - 200mg 200mg Tablet, film coated 35,112,293 L.L
N06AB08 FAVERIN B Fluvoxamine maleate - 100mg 100mg Tablet, film-scored 1,291,433 L.L
A02BD08 PYLERA B Bismuth subcitrate potassium - 140mg, Tetracycline HCl - 125mg, Metronidazole - 125mg Capsule 6,156,142 L.L
C10BA05 ATOZET B Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 1,624,706 L.L
J01DD04 ROCEPHIN IM B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 731,050 L.L
L01AX03 TEMODAL B Temozolomide - 100mg 100mg Capsule 7,731,224 L.L
L01EX05 STIVARGA B Regorafenib - 40mg 40mg Tablet, film coated 272,778,486 L.L
N03AX18 VIMPAT B Lacosamide - 200mg 200mg Tablet, film coated 13,357,859 L.L
N06AB10 CIPRALEX B Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 1,548,107 L.L
R06AX13 CLARITINE B Loratadine (micronised) - 5mg/5ml 5mg/5ml Syrup 430,030 L.L
A11EA BECOZYME B Vitamin B5 - 6mg/2ml, Vitamin B6 - 4mg/2ml, Vitamin PP - 40mg/2ml, Vitamin B2 - 5.47mg/2ml, Vitamin B1 - 10mg/2ml Injectable solution 662,514 L.L
    ...
    161
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025